EVGN:NASDAQ
Evogene
0,39 USD
arrow_upward
+0,96%(+0,0037) 1 d.
0,38 USD
arrow_downward
-2,00% (-0,0078)bedtimePo uzavretí
Zavreté: 13. 10., 16:00:00 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre EVGN…
Otvoriť
0,38 USD
Vysoká
0,40 USD
Nízka
0,37 USD
Trh. kap.
6,98 mil.
Priem. obj.
2,57 mil.
Objem
87,65 tis.
Max. za 52 týž.
1,49 USD
Min. za 52 týž.
0,35 USD
Výnosy na akciu
-0,90 USD
Beta
1,44
Akcie v obehu
18,05 mil.
Počet zamestnancov
52
Otvoriť
0,38 USD
Vysoká
0,40 USD
Nízka
0,37 USD
Trh. kap.
6,98 mil.
Priem. obj.
2,57 mil.
Objem
87,65 tis.
Max. za 52 týž.
1,49 USD
Min. za 52 týž.
0,35 USD
Výnosy na akciu
-0,90 USD
Beta
1,44
Akcie v obehu
18,05 mil.
Počet zamestnancov
52
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
The Globe and Mail
·
pred 36 minútami
Kaplan Fox Encourages Fluence Energy, Inc. (NASDAQ: FLNC) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 27, 2026
TradingView
·
pred 41 minútami
S&P 500 Ends Flat, While Nasdaq Drops As Memory Chipmakers Sell Off — BAC, GME, SPCX, ARM, QCOM In Focus
MarketBeat
·
pred 57 minútami
EverQuote (NASDAQ:EVER) Director Sells 1,593 Shares of Stock
Investor's Business Daily
·
pred 3 hodinami
Dow Jones Futures: Stock Market Holds Up As Meta, AMD Lead Buys; ASML, CPI Inflation Due
Profil
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
Informácie o subjekte Evogene